Autologous cell therapy (ACT) is a new therapeutic approach for diabetic patients with no-option chronic limb-threatening ischemia (NO-CLTI). The aim of our study was to quantify cell populations of cell therapy products (CTPs) obtained by three different isolation methods and to correlate their numbers with changes in transcutaneous oxygen pressure (TcPO2). CTPs were separated either from stimulated peripheral blood (PB) (n = 11) or harvested from bone marrow (BM) processed either by Harvest SmartPReP2 (n = 50) or sedimented with succinate gelatin (n = 29). The clinical effect was evaluated by the change in TcPO2 after 1, 3 and 6 months. TcPO2 increased significantly in all three methods at each time point in comparison with baseline values (p < .01) with no significant difference among them. There was no correlation between the change in TcPO2 and the size of injected cell populations. We only observed a weak correlation between the number of injected white blood cells (WBC) and an increase in TcPO2 at 1 and 3 months. Our study showed that all three isolation methods of ACT were similarly relatively efficient in the treatment of NO-CLTI. We observed no correlation of TcPO2 increase with the number of injected monocytes, lymphocytes or CD34+. We observed a weak correlation between TcPO2 increase and the number of injected WBCs.
Dalla PaolaLCimagliaPCaroneA, et al.Limb salvage in diabetic patients with no-option critical limb ischemia: outcomes of a specialized center experience. Diabet Foot Ankle. 2019;10(1):1696012.
2.
FuruyamaTOnoharaTYamashitaS, et al.Prognostic factors of ulcer healing and amputation-free survival in patients with critical limb ischemia. Vascular. 2018;26(6):626-633.
3.
BaltzisDEleftheriadouIVevesA. Pathogenesis and treatment of impaired wound healing in diabetes mellitus: new insights. Adv Ther. 2014;31(8):817-836.
4.
LopesLSetiaOAurshinaA, et al.Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research. Stem Cell Res Ther. 2018;9(1):188.
5.
HumphreyJAKanthasamySCoughlinPCollAPRobinsonAAH. Outcome of trans-metatarsal amputations in patients with diabetes mellitus. Foot (Edinb). 2019;40:22-26.
6.
SoderstromMIArvelaEMKorhonenM, et al.Infrapopliteal percutaneous transluminal angioplasty versus bypass surgery as first-line strategies in critical leg ischemia: a propensity score analysis. Ann Surg. 2010;252(5):765-773.
7.
ConteMSBradburyAWKolhP, et al.Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1-S109. e133.
8.
DubskyMJirkovskaABemR, et al.Comparison of the effect of stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia. Cytotherapy. 2014;16(12):1733-1738.
9.
LawallHBramlagePAmannB. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 2011;53(2):445-453.
10.
LuDJiangYDengW, et al.Long-term outcomes of BMMSC compared with BMMNC for treatment of critical limb ischemia and foot ulcer in patients with diabetes. Cell Transplant. 2019;28(5):645-652.
11.
MohamedSAHowardLMcInerneyV, et al.Autologous bone marrow mesenchymal stromal cell therapy for “no-option” critical limb ischemia is limited by karyotype abnormalities. Cytotherapy. 2020;22(6):313-321.
12.
DongZPanTFangY, et al.Purified CD34(+) cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine. 2018;35:46-57.
13.
Wahid SFAIsmailNAWan JamaludinWF, et al.Autologous cells derived from different sources and administered using different regimens for “no-option” critical lower limb ischaemia patients. Cochrane Database Syst Rev. 2018;8:CD010747.
14.
BenoitEO’DonnellTFJr.IafratiMD, et al.The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med2011;9:165.
15.
PignonBSevestreMAKanagaratnamL, et al.Autologous bone marrow mononuclear cell implantation and its impact on the outcome of patients with critical limb ischemia- results of a randomized, double-blind, placebo-controlled trial. Circ J. 2017;81(11):1713-1720.
16.
SharmaSPandeyNNSinhaM, et al.Randomized, double-blind, placebo-controlled trial to evaluate safety and therapeutic efficacy of angiogenesis induced by intraarterial autologous bone marrow-derived stem cells in patients with severe peripheral arterial disease. J Vasc Interv Radiol. 2021;32(2):157-163.
17.
SzaboGVKovesdZCserepesJDaroczyJBelkinMAcsadyG. Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up. Cytotherapy. 2013;15(10):1245-1252.
18.
LiMZhouHJinXWangMZhangSXuL. Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: preliminary clinical results. Exp Clin Transplant. 2013;11(5):435-439.
19.
TeraaMSprengersRWSchutgensRE, et al.Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled rejuvenating endothelial progenitor cells via transcutaneous intra-arterial supplementation (JUVENTAS) trial. Circulation. 2015;131(10):851-860.
20.
Arevalo-TurrubiarteMOlmeoCAccorneroPBarattaMMartignaniE. Analysis of mesenchymal cells (MSCs) from bone marrow, synovial fluid and mesenteric, neck and tail adipose tissue sources from equines. Stem Cell Res. 2019;37:101442.
21.
DingDCChangYHShyuWCLinSZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-347.
22.
GuoYZhangZXuX, et al.Menstrual blood-derived stem cells as delivery vehicles for oncolytic adenovirus virotherapy for colorectal cancer. Stem Cells Dev. 2019;28(13):882-896.
23.
DubskyMJirkovskaABemR, et al.Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev. 2013;29(5):369-376.
24.
DubskyMJirkovskaABemRNemcovaAFejfarovaVJudeEB. Cell therapy of critical limb ischemia in diabetic patients—state of art. Diabetes Res Clin Pract. 2017;126:263-271.
25.
SchaperW. Collateral circulation: past and present. Basic Res Cardiol. 2009;104(1):5-21.
26.
MillsJLSr.ConteMSArmstrongDG, et al.The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220-234. e221–222.
27.
SermsathanasawadiNPruekprasertKChruewkamlowN, et al.Peripheral blood mononuclear cell transplantation to treat no-option critical limb ischaemia: effectiveness and safety. J Wound Care. 2021;30(7):562-567.
28.
RabbanySYHeissigBHattoriKRafiiS. Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization. Trends Mol Med. 2003;9(3):109-117.
29.
MedinaRJBarberCLSabatierF, et al.Endothelial progenitors: a consensus statement on Nomenclature. Stem Cells Transl Med. 2017;6(5):1316-1320.
30.
TeraaMGremmelsHWijnandJGJVerhaarMC. Cell therapy for chronic limb-threatening ischemia: current evidence and future directions. Stem Cells Transl Med. 2018;7(12):842-846.
31.
KudoFANishibeTNishibeMYasudaK. Autologous transplantation of peripheral blood endothelial progenitor cells (CD34+) for therapeutic angiogenesis in patients with critical limb ischemia. Int Angiol. 2003;22(4):344-348.
32.
CaseJMeadLEBesslerWK, et al.Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol. 2007;35(7):1109-1118.
33.
SchirmerSHvan NooijenFCPiekJJvan RoyenN. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart. 2009;95(3):191-197.
34.
BernardiniCBertocchiMZannoniA, et al.Constitutive and LPS-stimulated secretome of porcine vascular wall-mesenchymal stem cells exerts effects on in vitro endothelial angiogenesis. BMC Vet Res. 2019;15(1):123.
PysnaABemRNemcovaA, et al.Endothelial progenitor cells biology in diabetes mellitus and peripheral arterial disease and their therapeutic potential. Stem Cell Rev Rep. 2019;15(2):157-165.
37.
TournoisCPignonBSevestreMA, et al.Cell therapy in critical limb ischemia: a comprehensive analysis of two cell therapy products. Cytotherapy. 2017;19(2):299-310.
38.
JavorkovaEMatejckovaNZajicovaA, et al.Immunomodulatory properties of bone marrow mesenchymal stem cells from patients with amyotrophic lateral sclerosis and healthy donors. J Neuroimmune Pharmacol. 2019;14(2):215-225.
39.
WagnerWFeldmannREJr.SeckingerA, et al.The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol2006;34(4):536-548.
40.
WijnandJGJTeraaMGremmelsH, et al.Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia. J Vasc Surg. 2018;67(2):656-661.
41.
Peeters WeemSMTeraaMde BorstGJVerhaarMCMollFL. Bone marrow derived cell therapy in critical limb ischemia: a meta-analysis of randomized placebo controlled trials. Eur J Vasc Endovasc Surg. 2015;50(6):775-783.
42.
GuptaPKChullikanaAParakhR, et al.A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013;11:143.
43.
LuDChenBLiangZ, et al.Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92(1):26-36.
44.
ChruewkamlowNPruekprasertKPhutthakunphithakP, et al.Novel culture media enhances mononuclear cells from patients with chronic limb-threatening ischemia to increase vasculogenesis and anti-inflammatory effect. Stem Cell Res Ther. 2021;12(1):520.
45.
BoonkaewBSuwanpitakSPattanapanyasatKSermsathanasawadiNWattanapanitchM. Efficient generation of endothelial cells from induced pluripotent stem cells derived from a patient with peripheral arterial disease. Cell Tissue Res. 2022;388(1):89‐104. doi:https://doi.org/10.1007/s00441-022-03576-2
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
